Sorry, you need to enable JavaScript to visit this website.

First-line Biologic Access | SIMPONI ARIA® (golimumab) | HCP
  1. Access and Affordability
  2. First-line Biologic Access for SIMPONI ARIA®

ACCESS AND AFFORDABILITY

FIRST-LINE BIOLOGIC ACCESS WITH NO SUBCUTANEOUS STEP THERAPY IS AVAILABLE NATIONWIDE FOR

90%

OF COMMERCIAL PATIENTS

Under the Medical Benefit1*
Coverage rate is for rheumatoid arthritis and psoriatic arthritis only.

100%

OF MEDICARE
PART B PATIENTS1*

*These percentages may not represent 100% of formulary lives due to data limitations.
 

Reference: 1. Managed Markets Insight & Technology, LLC™, a trademark of MMIT, as of June 2022.

LEARN MORE ABOUT LOCAL COVERAGE FOR SIMPONI ARIA® IN YOUR AREA

SUPPORT FOR PATIENTS USING COMMERCIAL OR PRIVATE INSURANCE TO PAY FOR MEDICATION

Janssen CarePath Savings Program can help eligible patients save on their out-of-pocket medication costs for SIMPONI ARIA®.

Your eligible patients will pay $5 per infusion with a $20,000 maximum program benefit per calendar year. Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. Terms expire at the end of each calendar year and may change. Program does not cover the cost to give patients their treatments. See full eligibility requirements

 

Online enrollment and tracking of patient Savings Program benefits by you, the pharmacy, or the patient

Providers can enroll and help manage patients' Savings Program benefits with a Provider Portal Account at JanssenCarePathPortal.com

Patients can manage Savings Program Benefits and more on their Janssen CarePath Account at MyJanssenCarePath.com